Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-3: Loncastuximab Tesirine + Ibrutinib in Advanced DLBCL or MCL
NCT03684694Phase 2Terminated
- Sponsor
- ADC Therapeutics
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), sponsored by ADC Therapeutics. Started Dec 2018; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03684694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684694.